Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 4/2016

01-03-2016 | AdisInsight Report

Brivaracetam: First Global Approval

Author: Anthony Markham

Published in: Drugs | Issue 4/2016

Login to get access

Abstract

Brivaracetam (Briviact®), a 4-n-propyl analogue of levetiracetam developed by UCB Pharma, has been approved in the EU as an adjunctive therapy for the treatment of partial-onset seizures. Brivaracetam binds to synaptic vesicle glycoprotein 2a (SV2A) in the brain with greater selectivity and 15- to 30-fold higher affinity than levetiracetam, as demonstrated in preclinical models, and has demonstrated efficacy in reducing the frequency of partial onset seizures in clinical trials. This article summarizes the milestones in the development of brivaracetam leading to this first approval for use as adjunctive therapy for uncontrolled partial-onset seizures in adults with epilepsy.
Literature
1.
Gillard M, Fuks B, Leclercq K, et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1):36–44.CrossRefPubMed
2.
3.
4.
UCB S.A. CHMP recommends EU approval for UCB’s new drug brivaracetam for people with epilepsy [media release]. 2015. http://​www.​ucb.​com. Accessed 25 Jan 2016.
5.
Matagne A, Margineanu DG, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154(8):1662–71.CrossRefPubMedPubMedCentral
6.
Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–9.CrossRefPubMed
7.
Rolan P, Sargentino-Maier ML, Pigeolet E. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66:71–5.CrossRefPubMedPubMedCentral
8.
Sargentini-Maier ML, Sokalski A, Boulanger P, et al. Brivaracetam disposition in renal impairment. J Clin Pharmacol. 2012;52(12):1927–33.CrossRefPubMed
9.
Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol. 2013;53(6):633–41.CrossRefPubMed
10.
Stockis A, Chanteux H, Rosa M, et al. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015;113:19–27.CrossRefPubMed
11.
Stockis A, Kruithof AC, Van Gerven JM, et al. Interaction study between brivaracetam and ethanol in healthy subjects [abstract no. 2.307]. Epilepsy Curr. 2015;15(Suppl 1):332.
12.
Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia. 2014;55(3):e27–31.CrossRefPubMed
13.
Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47–56.CrossRefPubMed
14.
Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55:57–66.CrossRefPubMed
15.
Pack AM. Brivaracetam, a novel antiepileptic drug: Is it effective and safe? Results from one phase III randomized trial. Epilepsy Curr. 2014;14(4):196–8.CrossRefPubMedPubMedCentral
16.
Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890–8.CrossRefPubMed
17.
Beydoun A, Semah F, Villanueva V, et al. Efficacy of brivaracetam stratified according to pathological substrate: findings from a phase 3 clinical trial [abstract no. 2.253]. In: 69th Annual Meeting of the American Epilepsy Society; 2015.
18.
Quarato PP, Whitesides J, D’Souza J, et al. Efficacy and safety of adjunctive brivaracetam for partial-onset (focal) seizures: pooled results from three fixed-dose, randomised, double-blind, placebo-controlled phase III studies. Epilepsia. 2015;56(Suppl 1):208.
19.
Kwan P, Trinka E, Van Paesschen W, et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55(1):38–46.CrossRefPubMed
20.
French JA, Costantini C, Brodsky A, et al. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010;75(6):519–25.CrossRefPubMed
21.
Van Paesschen W, Hirsch E, Johnson M, et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54(1):89–97.CrossRefPubMed
22.
Yates SL, Fakhoury T, Liang W, et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52:165–8.CrossRefPubMed
23.
UCB. UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam [media release]. 2015. http://​www.​ucb.​com. Accessed 21 Jan 2016.
Metadata
Title
Brivaracetam: First Global Approval
Author
Anthony Markham
Publication date
01-03-2016
Publisher
Springer International Publishing
Published in
Drugs / Issue 4/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0555-6

Other articles of this Issue 4/2016

Drugs 4/2016 Go to the issue

AdisInsight Report

Lesinurad: First Global Approval

Review Article

Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions

Current Opinion

Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents

Review Article

Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives

Therapy in Practice

Therapeutic Strategies for the Treatment of Severe Cushing’s Syndrome

Leading Article

Pharmacotherapy for Fragile X Syndrome: Progress to Date